ACA
AIMT

Affinity Capital Advisors’s Aimmune Therapeutics AIMT Stock Holding History

Affinity Capital Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,087
Closed -$338K – 123
2019
Q4 		$338K Buy
+10,087
New +$282K 0.22% 72

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Affinity Capital Advisors's AIMT Position: Q1 2020 in Review

Affinity Capital Advisors sold out of Aimmune Therapeutics (AIMT) in Q1 2020, closing a stake of 10,087 shares — an estimated $338K sold.

Affinity Capital Advisors first reported a position in AIMT in Q4 2019 and held it in 1 quarter. The position peaked at $338K in Q4 2019. 161 funds tracked by Wall St. Rank hold AIMT as of Q1 2020.

  • Affinity Capital Advisors reported no remaining Aimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Affinity Capital Advisors sold 10,087 Aimmune Therapeutics shares in Q1 2020, an estimated $338K.
  • Affinity Capital Advisors first reported a position in Aimmune Therapeutics in Q4 2019 and held it in 1 quarter.
  • Affinity Capital Advisors's Aimmune Therapeutics position peaked at $338K in Q4 2019.
  • 161 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2020.

Based on Affinity Capital Advisors's 13F filing for Q1 2020, filed 23 Apr 2020.